This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sayegh MH and Turka LA (1998) The role of T-cell costimulatory activation pathways in transplant rejection N Engl J Med 338: 1813–1821
Larsen CP et al. (2005) Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5: 443–453
Tran HT et al. (2000) Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 11: 1903–1909
Kreis H et al. (2004) Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15: 809–817
Acknowledgements
The synopsis was written by Chloe Harman, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Sayegh, M., Chandraker, A. Does belatacept provide equivalent suppression of acute renal transplant rejection to ciclosporin?. Nat Rev Nephrol 2, 134–135 (2006). https://doi.org/10.1038/ncpneph0125
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneph0125